Milligene

Medigene is a clinical-stage biotechnology company focused on the discovery and development of differentiated T cell receptor engineered T cell (TCR-T) therapies for the treatment of solid tumors. The company utilizes its proprietary end-to-end platform to identify and characterize highly specific T cell receptors (TCRs) against cancer-specific antigens, including neoantigens like KRAS mutations. Medigene's lead program, MDG1015, is a first-in-class TCR-T therapy targeting NY-ESO-1/LAGE-1a and is advancing toward clinical trials. The company maintains strategic partnerships with major pharmaceutical entities to leverage its TCR discovery capabilities and expand its therapeutic reach.